Calamos Advisors
TVTX icon

Calamos Advisors’s Travere Therapeutics TVTX Stock Holding History

Calamos Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.92M Buy
121,755
+67,510
+124% +$2.99M 0.02% 504
2026
Q1 		$1.61M Sell
54,245
-18,060
-25% -$540K 0.01% 701
2025
Q4 		$2.76M Buy
+72,305
New +$2.35M 0.01% 594
2021
Q2 		– Sell
-102,633
Closed -$2.56M – 1009
2021
Q1 		$2.56M Buy
+102,633
New +$2.84M 0.01% 661

Other funds holding TVTX

SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
CFM
Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
BC
Burney Company Reston, Virginia $3.71B AUM 37.66% 1-Year Est. Return

Calamos Advisors's TVTX Position: Q2 2026 in Review

Calamos Advisors increased its Travere Therapeutics (TVTX) stake by 124% in Q2 2026, buying an estimated $2.99M and bringing the position to 121,755 shares worth $6.92M. The position accounts for 0.02% of the portfolio, ranked #504.

Calamos Advisors first reported a position in TVTX in Q1 2021 and has held it in 4 quarters since. 55 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Calamos Advisors held 121,755 shares of Travere Therapeutics worth $6.92M as of Q2 2026.
  • Calamos Advisors bought 67,510 Travere Therapeutics shares in Q2 2026, an estimated $2.99M.
  • Travere Therapeutics made up 0.02% of Calamos Advisors's portfolio in Q2 2026, its #504 holding.
  • Calamos Advisors first reported a position in Travere Therapeutics in Q1 2021 and has held it in 4 quarters since.
  • 55 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Calamos Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.